Skip to content
Catalyst

PapersPMID:34303665

Effect of resveratrol on inflammatory cytokines: A meta-analysis of randomized controlled trials.

European journal of pharmacology2021The record ↗

findings
2
compound
1
endpoints
2
  1. Finding, very limited evidencelowersInterleukin-6 concentration
  2. Finding, very limited evidencelowersTumour necrosis factor alpha concentration
Study, every finding
meta-analysis
  • “A significant reduction of IL-6 concentration was observed only in the patients receiving ≥500 mg/day dose of resveratrol (WMD = -1.89 pg/ml, 95% CI = -3.73 to -0.05, P = 0.04) with inter-study heterogeneity (I2 = 94.4%, P < 0.001).”
    Dose studied
    ≥500 mg/day (dose-stratified subgroup)
    Population
    Adults with inflammatory disease receiving ≥500 mg/day resveratrol (dose subgroup, one of 26 studies on IL-6 per Methods); the abstract does not report a significant result for the overall/lower-dose population.
  • “Analysis in the overall population showed a significant effect of resveratrol consumption in reducing serum TNF-α levels (WMD = -0.66 pg/ml, 95% CI = -1.05 to -0.27, P = 0.001).”
    Population
    Adults with inflammatory disease, overall pooled population across resveratrol RCTs (21 studies contributed to the TNF-α analysis per Methods).